KR102707381B1 - Hemostatic medical device in which hemostatics containing thrombin and carboxymethyl chitosan gel are mixed in the field - Google Patents

Abstract

A hemostatic medical device according to the present invention comprises a first syringe storing a hemostatic agent including thrombin, a second syringe storing a hydrogel (carboxymethyl chitosan gel) made by dispersing carboxymethyl chitosan in water, and a connecting tube member connecting the first and second syringes. The carboxymethyl chitosan gel is transferred to the first syringe, and the hemostatic agent is mixed with the carboxymethyl chitosan gel and applied to a bleeding site.

Description

{Hemostatic medical device in which hemostatics containing thrombin and carboxymethyl chitosan gel are mixed in the field}

The present invention relates to a hemostatic medical device, and more specifically, to a hemostatic medical device which can be used simply, quickly, and conveniently by mixing a hemostatic agent containing thrombin into a carboxymethyl chitosan gel for a bleeding patient competing for time in an emergency treatment site, an operating room, an emergency room, etc., and which can prevent contamination.

In general, bleeding occurs when blood vessels are damaged by physical trauma, including surgical operations. Depending on the extent of the injury, bleeding can result in blood loss that can affect the normal bodily functions of the individual, and in cases where bleeding occurs in non-distensible cavities of bones, the blood flowing out of the vessels can accumulate and cause damage to soft tissues due to increased pressure. If bleeding is left untreated, the bleeding will be stopped by a physiological process characterized by a complex chain reaction among blood vessels, platelets, and plasma factors. This process is called physiological hemostasis. In cases of minor superficial bleeding, this physiological hemostasis is sufficient to stop the bleeding.

However, when the bleeding arises from more serious injuries, particularly those involving large arteries or spilling blood from larger mucosal surfaces or from cavities without an outlet, surgical and/or medical hemostatic measures are required. Surgical hemorrhage control may include ligation or suturing of ruptured vessels, packing of cavities with cotton balls, and clotting of the tissue surfaces exposed to the ruptured vessels by application of heated instruments, cautery, or heated air.

For effective hemostasis, several hemostatic ingredients can be mixed and used. However, in cases where emergency treatment is required at the scene of an accident, it is inconvenient and time-consuming to mix and use these several hemostatic ingredients on a bleeding patient competing for time in an emergency room or operating room, and there is also a possibility of contamination when mixing.

Therefore, for effective hemostasis, a medical device that can mix and use various hemostatic ingredients quickly, easily, and without the possibility of contamination is needed. In addition, the bleeding site or surgical site may have adhesions in the future, so it is necessary to prevent adhesions along with hemostasis.

United States Patent Application Publication No. US 2021/0015964 (Application Publication: January 21, 2021)

The present invention has been proposed to solve the above problems, and its purpose is to provide a hemostatic medical device that can be used by quickly mixing various hemostatic components without risk of contamination on a bleeding patient competing for time in an emergency treatment site, an operating room, an emergency room, etc.

Another object of the present invention is to provide a hemostatic medical device that prevents adhesion while stopping hemorrhage at a bleeding site.

In order to achieve the above task, a hemostatic medical device (100) according to the present invention may include a first syringe (110) having a hemostatic agent stored therein; a second syringe (120) having a hydrogel stored therein; and a connecting tube member (130) that connects the first and second syringes (110)(120) and serves as a passage through which the hydrogel and the hemostatic agent mixed in the hydrogel move between the first and second syringes (110)(120).

The above hydrogel is a carboxymethyl chitosan gel made by mixing and stirring carboxymethyl chitosan in water, and the hemostatic agent may contain thrombin as a main component. The hemostatic agent may be mixed with the carboxymethyl chitosan gel to form a hemostatic composition, which may then be used on a bleeding site. This mixing may be performed immediately before use on a bleeding patient at an emergency treatment site, an operating room, an emergency room, etc. In addition, the hemostatic medical device (100) may eliminate the possibility of contamination that may occur during the mixing process.

It is preferable that carboxymethyl chitosan is included in an amount of 4 to 10 wt% relative to the total weight of the carboxymethyl chitosan gel, and that the carboxymethyl chitosan gel has a viscosity of 100 CPS to 4500 CPS.

The above hemostatic agent is thrombin (or its precursor, prothrombin), and 1 to 20 mg or 50 to 1,000 IU of thrombin per 1 ml of carboxymethylchitosan gel in the second syringe (120) can be stored in the first syringe (110).

The above connecting member (130) may include a pipe body (131); and screw threads (132) formed at both ends of the pipe body (131).

A groove (113) may be formed at the tip of the first and second syringes (110)(120), and a screw thread (114) may be formed on the inner surface of the groove (113). After the end of the tube body (131) is inserted into the groove (113), the screw thread (132)(114) may be screwed together, thereby connecting the tube body (131) and the first and second syringes (110)(120).

The connecting member (130) may further include wings (133). The wings (133) are formed to protrude outwardly from the outer surface of the pipe body (131), and at least two wings (133) are formed, and the wings (133) can be used to rotate the pipe body (131) by hand for screw connection of the pipe body (131).

The hemostatic medical device according to the present invention can be used by quickly mixing various hemostatic components without risk of contamination on a bleeding patient competing for time in an emergency treatment site, operating room, emergency room, etc.

In addition, the hemostatic medical device according to the present invention can prevent adhesion along with hemostasis at the bleeding site.

FIG. 1 is a flow chart showing a process for manufacturing a carboxymethyl chitosan gel according to a preferred embodiment of the present invention.
Figure 2 is an exploded perspective view showing a hemostatic medical device according to a preferred embodiment of the present invention.
Figure 3 is a perspective view showing a connecting tube member of a hemostatic medical device.
Figure 4 is a perspective view showing a combined medical device for hemostasis.
Figure 5 is a cross-sectional view showing the connection portion of the syringe and the connecting tube member.

Hereinafter, the present invention will be described in detail with reference to the attached drawings. Prior to this, the terms or words used in this specification and claims should not be interpreted as limited to their usual or dictionary meanings, and should be interpreted as meanings and concepts that conform to the technical idea of the present invention based on the principle that the inventor can appropriately define the concept of the term in order to explain his or her own invention in the best way. Therefore, the embodiments described in this specification and the configurations illustrated in the drawings are merely embodiments of the present invention and do not represent all of the technical idea of the present invention, and it should be understood that there may be various equivalents and modified examples that can replace them at the time of this application.

According to the present invention, a hemostatic agent containing thrombin and/or a precursor thereof is stored in a first syringe, and a carboxymethyl chitosan gel is stored in a second syringe. Then, in cases of surgery or emergency treatment, the first and second syringes are connected at the scene, the hemostatic agent and carboxymethyl chitosan gel are mixed, and then directly applied (applied or injected) to the bleeding site. In this specification, the hemostatic agent refers to the hemostatic component stored in the first syringe. Although carboxymethyl chitosan gel also has a hemostatic effect, the distinction is made in this way in order to conveniently refer to the hemostatic component stored in the first syringe. The hemostatic agent may contain thrombin and/or a precursor thereof as its main component.

1. Carboxymethylchitosan gel and thrombin

(1) Carboxymethylchitosan gel

Figure 1 is a flow chart showing the manufacturing process of carboxymethyl chitosan gel.

The above manufacturing process includes a step (S210) of mixing biodegradable carboxymethyl chitosan powder into water, for example, ultrapure water (UPW), to create a gel-like mixture, a step (S220) of sterilizing the mixture by heating, a step (S230) of concentrating the sterilized mixture, and a step (S240) of removing air bubbles contained in the concentrated mixture.

As is known, carboxymethyl chitosan is a derivative of chitosan. Chitosan is insoluble in neutral water, but carboxymethyl chitosan is soluble even in neutral water. Preferably, in step S210, carboxymethyl chitosan is mixed and stirred in water so that the concentration of carboxymethyl chitosan becomes 2 to 6 wt%.

And, in step S230, the gel can be concentrated so that the content (concentration) of carboxymethyl chitosan in the gel becomes 3 to 8 wt%. In this way, in the present invention, after a low-viscosity gel with a low content of carboxymethyl chitosan is produced, the gel is gradually concentrated while stirring to produce a high-viscosity gel with a high content of carboxymethyl chitosan and uniformity.

The gel produced through the above process has a composition ratio of 4 to 10 wt% of carboxymethyl chitosan, a moisture content of 87 wt% or less or 97 wt% or less, and a viscosity of 100 CPS to 4,500 CPS.

On the other hand, if the gel-type hemostatic agent does not have a sufficient retention time in the body, it is difficult to exhibit the intended adhesion prevention effect. The carboxymethyl chitosan gel according to the present invention is slowly decomposed into low-molecular-weight substances at the application site (e.g., surgical site) when applied in the body, so that more than 55% remains after 2 weeks and about 10% remains after 4 weeks, thereby maintaining the optimal retention time in the body for wound healing. Therefore, the incidence of adhesion at the relevant site is significantly low.

Carboxymethyl chitosan plays a very important role in blood coagulation and can promote platelet adhesion and aggregation, which promotes hemostasis and thrombosis. In addition, carboxymethyl chitosan has a positive charge, and ionic attraction occurs between it and red blood cells, which have a negative charge. Therefore, when carboxymethyl chitosan gel is applied to a wound, it attracts red blood cells and seals the area, so it has an excellent hemostatic effect.

In addition, since carboxymethyl chitosan gel can be applied inside the body using a syringe, etc. after surgery, it can be easily used in narrow areas of the body where existing hemostatic agents or anti-adhesion agents were difficult to apply.

If the carboxymethyl chitosan content is less than 4 wt% based on the weight of the entire gel, it is insufficient to achieve the desired effects as mentioned above, and if the carboxymethyl chitosan content exceeds 10 wt%, the viscosity becomes too high to be practically difficult to manufacture. In addition, if the viscosity of the gel is less than 100 CPS, there is a problem that it easily flows down due to insufficient adhesion to the application area, and if the viscosity of the gel exceeds 4,500 CPS, there is a problem that the viscosity becomes too high to be practically difficult to manufacture.

The carboxymethyl chitosan gel manufactured by the above process is stored in the second syringe. 1 to 20 mg or 50 to 1,000 IU of a hemostatic agent (including thrombin and/or its precursor) per 1 ml of carboxymethyl chitosan gel can be stored in the first syringe. If the amount of thrombin is less than the lower limit, the hemostatic effect is reduced, and if it is more than the upper limit, the hemostatic effect does not increase, but there is a problem that mixing with the carboxymethyl chitosan gel is difficult.

(2) Thrombin and/or its precursors;

As is known, thrombin is a proteolytic enzyme involved in blood coagulation, catalyzing a reaction that hydrolyzes soluble fibrinogen in blood, which is the essence of blood coagulation, and changes it into insoluble fibrin. In addition, thrombin can induce platelet activation in the process of forming fibrin by activating blood coagulation factors, which is a secondary hemostasis process.

In the present invention, known thrombin and its precursor (prothrombin) can be used. In addition, bovine thrombin is preferable as thrombin, but is not necessarily limited thereto.

Thrombin and/or its precursor (prothrombin) are contained in the first syringe. Then, immediately before emergency hemostasis or at the surgical site, the thrombin (and/or its precursor, prothrombin) in the first syringe and the carboxymethyl chitosan gel in the second syringe are mixed to form a hemostatic composition, which is then immediately applied (applied or injected) to the bleeding site, which will be described below.

2. Medical devices for hemostasis

FIG. 2 is an exploded perspective view showing a hemostatic medical device according to the present invention, FIG. 3 is a perspective view showing a connecting tube member of the hemostatic medical device, and FIG. 4 is a combined perspective view showing the hemostatic medical device.

As shown in the drawing, the hemostatic medical device (100) includes a first syringe (110), a second syringe (120), and a connecting tube member (130).

The first syringe (110) includes a barrel (111) and a plunger (112). A hemostatic agent is stored (stored) in the internal space of the barrel (111). When an external force is applied, the plunger (112) slides inside the barrel (111) and moves forward and backward along the longitudinal direction of the barrel (111).

As shown in Fig. 5, a groove (113) is formed at the tip of the barrel (111). The groove (113) is connected to the internal space of the barrel (111). A screw thread (114) and a sleeve (115) are formed inside the groove (113). The screw thread (114) and the sleeve (115) will be described below.

The second syringe (120) has the same structure as the first syringe (110). The barrel (111) of the second syringe (120) contains (stores) a carboxymethyl chitosan gel.

The connecting pipe member (130) connects the first and second syringes (110) and (120). The connecting pipe member (130) includes a pipe body (131), screw threads (132) formed at both ends of the pipe body (131), and wings (133) formed on the outer surface of the pipe body (131).

One end of the tube body (131) is connected to a groove (113) of a first syringe (110), and the other end is connected to a groove (113) of a second syringe (120). Through the tube body (131), the carboxymethyl chitosan gel is moved to the first syringe (110), and the hemostatic component dissolved in the carboxymethyl chitosan gel is moved to the second syringe (120). The length of the tube body (131) can be increased or decreased as needed.

Screw threads (132) are formed at both ends of the pipe body (131). Screw threads (132) are screw-connected with screw threads (114). By screw-connecting the screw threads (132) and (114), the connecting pipe member (130) is removably connected to the first and second syringes (110) and (120) so as to be watertight.

The wings (133) are formed to protrude outwardly on the outer surface of the pipe body (131) to rotate the pipe body (131) for the screw connection. In order to effectively rotate the pipe body (131), it is preferable that two wings (133) are formed at 180° intervals (one pair), and more preferably, the two pairs of wings (133) are formed on both sides of the longitudinal center of the pipe body (131). In addition, it is preferable that the two wings (133, one pair of wings) facing each other are formed to be slightly inclined rather than horizontally, but are positioned on the same plane for effective rotation, and it is preferable that the two pairs of wings (133) formed on both sides of the longitudinal center are positioned on different planes (i.e., positioned on planes intersecting each other).
That is, two pairs of wings (133) are formed on both sides of the longitudinal center of the main body (131), and two wings (133) are formed on the same plane at 180-degree intervals on one side of the central side, and two wings (133) are formed on the same plane at 180-degree intervals on the other side of the central side, and in order to effectively rotate the connecting pipe member (130), the plane formed by the two wings (133) on the one side and the plane formed by the two wings (133) on the other side are formed to be inclined so as to intersect with each other.

As shown in Fig. 5, after inserting the end of the pipe body (131) between the sleeve (115) and the inner surface of the groove (113), the wing (133) is held and rotated so that the screw threads (132) (114) are screw-connected.

Meanwhile, the sleeve (115) is a tube formed to be spaced apart from the inner surface of the groove (113) by a predetermined interval, and since its inner end is blocked, it limits the insertion length of the tube body (131).

After connecting the first and second syringes (110)(120) using the connecting tube member (130), the plungers (112) of the first and second syringes (110)(120) are alternately pushed repeatedly, so that the carboxymethyl chitosan gel moves to the first syringe (110) through the tube body (130), whereby the hemostatic agent is dissolved and/or mixed, and the hemostatic component of the hemostatic agent moves together with the gel toward the second syringe (120), repeatedly. In this process, the hemostatic agent is completely mixed with the carboxymethyl chitosan gel, and the mixed hemostatic component is applied or injected to the bleeding site using the first syringe (110) or the second syringe (120).

Preferably, after the mixing is completed, a hose (not shown in the drawing) may be connected to the tip of the first syringe (110) or the second syringe (120) to inject the hemostatic component into the human body through the hose. Preferably, one end of the hose is inserted between the inner surface of the sleeve (115) and the groove (113), and the other end of the hose is brought close to the bleeding site, and then the plunger (112) is moved to apply or inject the hemostatic component. The length of the hose may be adjusted according to the location and depth of the bleeding site, and is preferably transparent and flexible, but is not necessarily limited thereto.

3. Test

Hereinafter, experimental examples will be described to help understand the present invention. However, the experimental examples according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the experimental examples below. The experimental examples of the present invention are provided to more completely explain the present invention to a person having average knowledge in the art.

(1) Experimental Example 1-1

A carboxymethyl chitosan gel is prepared by the method described in 1.(1) above. Specifically, a 2 wt% mixture of carboxymethyl chitosan is prepared by mixing and stirring carboxymethyl chitosan powder in ultrapure water (UPW). Subsequently, the mixture is filtered and sterilized, and the mixture is concentrated in a double boiler, filtered, and air bubbles are removed, thereby preparing a gel having a 4 wt% carboxymethyl chitosan content and a viscosity of 100 CPS.

The carboxymethyl chitosan gel manufactured in this manner is stored in the second syringe (120), and thrombin is stored in the first syringe (110). At this time, 4 mg of thrombin is stored per 1 ml of carboxymethyl chitosan gel.

(2) Experimental example 1-2

The manufactured gel is the same as Example 1 except that the content of carboxymethyl chitosan in the manufactured gel is 10 wt% and the viscosity is 4,500 CPS. The manufactured carboxymethyl chitosan gel is stored in a second syringe (120) and thrombin is stored in a first syringe (110).

(3) Comparative Example 1-1

A carboxymethyl chitosan gel is manufactured in the same manner as in Experimental Example 1-1, but the content of carboxymethyl chitosan in the gel is 3 wt% and the viscosity of the gel is 90 CPS. The gel is then stored in a second syringe (120). The amount of carboxymethyl chitosan gel stored in the second syringe (120) is the same as in Experimental Example 1-1.

Then, the same amount of thrombin as in Experimental Example 1-1 is stored in the first syringe (110).

(4) Comparative Example 1-2

The manufactured carboxymethyl chitosan gel is the same as Example 1-1, except that the content of carboxymethyl chitosan is 11 wt% and the viscosity of the gel is 4,600 CPS. The manufactured carboxymethyl chitosan gel is stored in a second syringe (120), and thrombin is stored in a first syringe (110). The amounts of carboxymethyl chitosan gel and thrombin stored in each syringe are the same as in Experimental Example 1-1.

(5) Comparative Example 1-3

It is the same as Example 1-1, except that saline solution is stored in the second syringe instead of the carboxymethyl chitosan gel. The amount of saline solution stored in the second syringe is the same as the amount (volume) of the carboxymethyl chitosan gel in Example 1-1, and the amount of thrombin stored in the first syringe is the same as the amount of thrombin stored in the first syringe in Example 1-1.

[Adhesion Test]

The adhesion test was performed on the hemostatic compositions of Experimental Examples 1-1 to 1-2 and Comparative Examples 1-1 to 1-3 as follows.

(1) Adhesion induction and adhesion prevention treatment in animal models

As shown in the table below, the anti-adhesion effect was evaluated using a rat cecum/abdominal wall abrasion model.

Experimental animals were 10 male rats per group, 6 weeks old. To induce adhesions, zoletil (40 mg/kg) and xylatine (5 mg/kg) were administered intraperitoneally to undertake general anesthesia. After removing the hair on the abdomen using a hair remover and disinfecting with 70% alcohol, the abdomen was incised 3 to 4 cm along the left 1 cm of the midline. Then, the cecum was taken out, and using a sterilized dry gauze, the serosa was damaged enough to cause bleeding so that the damaged surface of the cecum was in contact with the right abdominal wall, and both ends of the damaged surface were fixed to the cecum and the abdominal wall using sutures to promote adhesion formation. Then, a mixture of a hemostatic agent (hemostatic composition) and the carboxymethyl chitosan gel of Examples 1-1, 1-2 and Comparative Examples 1-1, 1-2, and 1-3 (Saline solution in Comparative Example 1-3) was injected between the damaged area and the abdominal wall, and the peritoneum and skin were each continuously sutured and disinfected.

14 days after the adhesion procedure, general anesthesia was administered, the abdomen was opened, and the degree of adhesion was visually observed. The degree of adhesion was evaluated according to the evaluation criteria in the table below, and the size of the adhesion was measured using a ruler.

(2) Results of adhesion degree and adhesion prevention effect measurement

As a result of measuring the degree of adhesion according to the above evaluation criteria, it was confirmed that adhesion was significantly inhibited in the cases of Examples 1-1 and 1-2 and Comparative Example 1-2 (see table below).

Example 1-1 showed a 61.9% increase in the adhesion degree improvement effect compared to Comparative Example 1-1, and Example 1-2 and Comparative Example 1-2 showed a 76.2% increase in the adhesion degree improvement effect compared to Comparative Example 1-1.

Comparative Example 1-1 is judged to have caused significant adhesion because the carboxymethyl chitosan content in the carboxymethyl chitosan gel was 3 wt%, so it did not remain in the wounded area for a long time, and the viscosity of the gel was low at 90 CPS, so it flowed to other areas.

In comparison, Comparative Example 1-2 appears to have failed to show an improved effect compared to Example 1-2 because the content of carboxymethyl chitosan and the viscosity of the gel were excessively large. On the other hand, as in Comparative Example 1-2, if the content of carboxymethyl chitosan exceeds 10 wt% and the viscosity of the gel exceeds 4500 CPS, the viscosity is so high that it is almost impossible to manufacture, which is not preferable.

Meanwhile, Comparative Example 1-3 was a case where saline solution was used instead of carboxymethyl chitosan gel, and it was found that the degree of adhesion occurrence was very severe.

Thus, Examples 1-1 and 1-2 have an appropriate content of carboxymethyl chitosan gel of 4 to 10 wt% and an appropriate viscosity of the gel of 100 to 4500 CPS, so that the gel remains for an appropriate amount of time to prevent adhesion in the body, and the appropriate viscosity reduces flowing out from the wound site (bleeding site) to other areas.

[Hemostasis test]

In order to confirm the hemostatic effect of the hemostatic composition according to the present invention, a rabbit mesentery cutting model was used. After inducing bleeding by cutting the mesentery, Examples 1-1 and 1-2 and Comparative Examples 1-1, 1-2 and 1-3 were applied respectively, and hemostatic pressure was attempted for 30 seconds to check whether bleeding occurred, and if bleeding occurred, hemostatic pressure was repeated for an additional 30 seconds. For 10 rabbits, the probability of successful hemostasis within 90 seconds and the time required for hemostasis were measured, and the results are shown in Table 1 below.

As shown in the table above, in Examples 1-1, 1-2 and Comparative Example 1-2, all 10 rabbits tested achieved hemostasis within 90 seconds, whereas in Comparative Example 1-1, only 7 out of 10 rabbits achieved hemostasis within 90 seconds, and in Comparative Example 1-3, only 5 out of 10 rabbits achieved hemostasis within 90 seconds, showing a statistically significant difference. Accordingly, it was confirmed that when the hemostatic composition according to the present invention is used, the hemostasis success rate is high and the hemostasis time is shortened, thereby exhibiting an excellent hemostatic effect.

Meanwhile, Comparative Example 1-2 showed no difference from Examples 1-1 and 1-2 in terms of hemostatic effect. However, as described above, the carboxymethyl chitosan gel of Comparative Example 1-2 is not preferable because its viscosity is too high and it is almost impossible to manufacture.

As described in the above test, the hemostatic compositions of Examples 1-1 and 1-2 have excellent hemostatic effects and anti-adhesion effects.

In comparison, Comparative Example 1-1 has poor adhesion prevention and hemostatic effects, Comparative Example 1-2 has similar adhesion prevention and hemostatic effects to Examples 1-1 and 1-2, but is nearly impossible to manufacture because its viscosity is too high and the gel component may remain in the body for too long, which is not desirable, and Comparative Example 1-3 has very poor adhesion prevention and hemostatic effects.

100: Medical device for hemostasis 110: First syringe
111 : Barrel 112 : Plunger
113 : Home 114 : Screw
115 : Sleeve 120 : Second Syringe
130: Connection pipe member 131: Pipe body
132 : Screw 133 : Wing

Claims (5)

A first syringe (110) having a hemostatic agent stored therein;
A second syringe (120) having a hydrogel stored therein; and,
It includes a connecting tube member (130) that connects the first and second syringes (110)(120) and serves as a passage through which the hydrogel and the hemostatic agent dissolved in the hydrogel move between the first and second syringes (110)(120);
The above hydrogel is a carboxymethyl chitosan gel made by mixing and stirring carboxymethyl chitosan in water, and the hemostatic agent includes thrombin.
The thrombin stored in the first syringe (110) is melted by the carboxymethyl chitosan gel stored in the second syringe (120) to form a hemostatic composition, which is then immediately used on the bleeding site.
Carboxymethyl chitosan is contained in an amount of 4 to 10 wt% relative to the total weight of the carboxymethyl chitosan gel, and the carboxymethyl chitosan gel has a viscosity of 100 CPS to 4500 CPS.
1 to 20 mg or 50 to 1,000 IU of thrombin per 1 ml of carboxymethylchitosan gel of the second syringe (120) is stored in the first syringe (110),
The connecting pipe absence (130) is
The body of the coffin (131); and,
Includes screw threads (132) formed at both ends of the main body (131);
A groove (113) is formed at the tip of the first and second syringes (110) (120), and a screw thread (114) is formed on the inner surface of the groove (113).
After the end of the pipe body (131) is inserted into the groove (113), the pipe body (131) and the first and second syringes (110) (120) are connected by screwing the screw threads (132) (114).
A hemostatic medical device characterized in that two pairs of wings (133) are formed on both sides of the longitudinal center of the main body (131), and two wings (133) are formed on the same plane at an interval of 180 degrees on one side of the central both sides, and two wings (133) are formed on the same plane at an interval of 180 degrees on the other side of the central both sides, and the plane formed by the two wings (133) on the one side and the plane formed by the two wings (133) on the other side are formed at an angle so as to intersect each other in order to effectively rotate the connecting pipe member (130). delete delete delete delete

Images